[HTML][HTML] Efficacy of monotherapy with biologics and JAK inhibitors for the treatment of rheumatoid arthritis: a systematic review
P Emery, JE Pope, K Kruger, R Lippe, R DeMasi… - Advances in …, 2018 - Springer
Despite recommendations suggesting that biological and targeted synthetic disease-
modifying antirheumatic drugs (b/tsDMARDs) should be used in combination with …
modifying antirheumatic drugs (b/tsDMARDs) should be used in combination with …
Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a …
R Fleischmann, E Mysler, S Hall, AJ Kivitz, RJ Moots… - The Lancet, 2017 - thelancet.com
Background Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid
arthritis. The Oral Rheumatoid Arthritis triaL (ORAL) Strategy aimed to assess the …
arthritis. The Oral Rheumatoid Arthritis triaL (ORAL) Strategy aimed to assess the …
Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials
Objectives Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid
arthritis (RA). We report an integrated safety summary of tofacitinib from two phase I, nine …
arthritis (RA). We report an integrated safety summary of tofacitinib from two phase I, nine …
[HTML][HTML] Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study
Background Final data are presented for the ORAL Sequel long-term extension (LTE) study
evaluating the safety and efficacy of tofacitinib 5 mg and 10 mg twice daily (BID) for up to 9.5 …
evaluating the safety and efficacy of tofacitinib 5 mg and 10 mg twice daily (BID) for up to 9.5 …
[HTML][HTML] The impact of biologics and tofacitinib on cardiovascular risk factors and outcomes in patients with rheumatic disease: a systematic literature review
M Nurmohamed, E Choy, S Lula, B Kola, R DeMasi… - Drug Safety, 2018 - Springer
Introduction Rheumatic diseases are autoimmune, inflammatory diseases often associated
with cardiovascular (CV) disease, a major cause of mortality in these patients. In recent …
with cardiovascular (CV) disease, a major cause of mortality in these patients. In recent …
Analysis of haematological changes in tofacitinib-treated patients with rheumatoid arthritis across phase 3 and long-term extension studies
H Schulze-Koops, V Strand, C Nduaka… - …, 2016 - academic.oup.com
Objectives. Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. The aim of
this analysis was to characterize changes in haematological parameters following tofacitinib …
this analysis was to characterize changes in haematological parameters following tofacitinib …
[HTML][HTML] Worldwide, 3-year, post-marketing surveillance experience with tofacitinib in rheumatoid arthritis
S Cohen, JR Curtis, R DeMasi, Y Chen, H Fan… - Rheumatology and …, 2018 - Springer
Introduction Post-marketing surveillance (PMS) is an integral part of monitoring adverse
events (AEs) following approval of new drugs. Tofacitinib is an oral Janus kinase inhibitor for …
events (AEs) following approval of new drugs. Tofacitinib is an oral Janus kinase inhibitor for …
[PDF][PDF] Risk factors for major adverse cardiovascular events in phase III and long‐term extension studies of tofacitinib in patients with rheumatoid arthritis
C Charles‐Schoeman, R DeMasi… - Arthritis & …, 2019 - Wiley Online Library
Objective Tofacitinib is an oral JAK inhibitor for the treatment of rheumatoid arthritis (RA).
This study was undertaken to evaluate the risk of major adverse cardiovascular events …
This study was undertaken to evaluate the risk of major adverse cardiovascular events …
[PDF][PDF] Changes in lipid levels and incidence of cardiovascular events following tofacitinib treatment in patients with psoriatic arthritis: a pooled analysis across phase …
DD Gladman, C Charles‐Schoeman… - Arthritis care & …, 2019 - Wiley Online Library
Objective The risk of cardiovascular disease (CVD) is higher in patients with psoriatic
arthritis (PsA) compared to the general population. Tofacitinib is an oral Janus kinase …
arthritis (PsA) compared to the general population. Tofacitinib is an oral Janus kinase …
Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial
V Strand, E Mysler, RJ Moots, GV Wallenstein… - RMD open, 2019 - rmdopen.bmj.com
Objective To provide the first direct comparison of patient-reported outcomes (PROs)
following treatment with tofacitinib monotherapy versus tofacitinib or adalimumab (ADA) in …
following treatment with tofacitinib monotherapy versus tofacitinib or adalimumab (ADA) in …